Sirtex Medical Ltd (SXMDF) 21.9500 $SXMDF
How To Profit From Australia's Healthiest Biotechs: Wilson HTM's Shane Storey
Life Sciences Report - Seeking Alpha - Thu Apr 16, 2:14PM CDT
Australia will always be known as a trove of natural resources, but its most precious treasure is the abundance of entrepreneurs who are all too happy to develop the country's intellectual assets. Shane Storey, head of research at Australia-based...
PHG: 28.33 (+0.40), RMD: 56.20 (-0.26)
Sirtex: Update On Study Results
Russell Muldoon - Seeking Alpha - Mon Mar 23, 6:15AM CDT
(Editor's Note: Investors should be mindful of the risks of transacting is securities with limited liquidity, such as SXMDF. Sirtex's listing in Australia, SRX.AX, offers stronger liquidity.) SIRFLOX Trial Results Despite our understanding of the...
Sirtex Slips On Its Beads After Trial Miss
EP Vantage - Seeking Alpha - Tue Mar 17, 3:07PM CDT
In its announcement today Sirtex Medical ( OTCPK:SXMDF ) said it was pleased to report the preliminary results of its phase III Sirflox study, but frankly that seems unlikely. The trial failed, and Sirtex's dreams of having a first-line therapy for...
Sirtex Medical: Strong Demand And New Market Potential
Russell Muldoon - Seeking Alpha - Fri Mar 13, 7:19AM CDT
(Editor's Note: Investors should be mindful of the risks of transacting is securities with limited liquidity, such as SXMDF. Sirtex's listing in Australia, SRX.AX, offers stronger liquidity.) Sirtex Medical Limited is an Australian-based medical...
Onxeo: An Upcoming Mid-Sized Pharma With Ambitions
Logribel Biostocks - at Seeking Alpha - Thu Mar 12, 1:58PM CDT
MACK: 12.66 (+0.34), RNN: 0.71 (+0.01), PTBI: 7.98 (-0.36), DARA: 0.68 (-0.06), BIND: 6.24 (unch)
Sirtex Medical Inc. Half-Year Dose Sales Surge 28 Percent in Advance of SIRFLOX Primary Endpoint Announcement
Business Wire - Wed Feb 18, 8:13AM CST
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), has announced that dose sales of SIR-Spheres(R) Y-90 resin microspheres in the Americas region grew more than 28 percent for the first half of the company's fiscal year compared to the same period last year, with 3,390 doses supplied for the period July through December 2014. The gross sales in the region equate to $54.3M in the first half of the current fiscal year compared to $39.8M from the prior year, a 36.7% increase. Globally the company announced sales of 4,950 doses, an increase of 26.3% over the previous corresponding six-month period.
FOXFIRE and FOXFIRE Global Studies Complete Patient Enrolment
CNW Group - Thu Jan 29, 10:22AM CST
Combined data from more than 1,000 patients being collected to assess overall survival (OS) benefit of adding first-line SIR-Spheres® Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer (mCRC)
Novel Drug Delivery System (NDDS) in Cancer Therapy Market - Global Industry Analysis to 2020 for the $15 Billion Market
M2 - Wed Nov 12, 3:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/ws3rns/ndds_in_cancer) has announced the addition of the "NDDS in Cancer Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global market for NDDS in cancer therapy was valued at USD 3,655.3 million in 2013 and is expected to reach USD 15,984.2 million in 2020, growing at a CAGR of 23.7% during the forecast period from 2014 to 2020 The world is witnessing a continuous rise in the incidence of various types of cancer. Clinical benefits of embolic agents and nanoparticles over other therapy and drug delivery systems; technological advances leading to the development of new and innovative therapy; and expanding therapeutic indications of existing NDDS are some of the major factors expected to drive growth of the global NDDS in cancer therapy market during the forecast period from 2014 to 2020. On the other hand, factors such as high treatment cost associated with NDDS, strict regulatory pathways and cost associated with new product development may restrict market growth to some extent. One of the major opportunities in this market is nano-enabled drug delivery systems as this segment has been anticipated to grow at the highest CAGR of 24.7% during the forecast period. Embolization particles, liquid embolics and nanoparticles as drug delivery systems altogether comprise the global market for NDDS in cancer therapy. PVA particles, microspheres, drug eluting beads (DEB) and selective internal radiation therapy (SIRT) are the major products under the embolization particles market segment, while Onyx LES and TRUFILL nBCA LES are the two major liquid embolic system brands. The liquid embolics market segment is expected to grow at a CAGR of 4.9% during the forecast period from 2014 to 2020. Nanoparticles in novel drug delivery systems have emerged as a promising technology to treat patients suffering from various types of cancer. The market for nanoparticles segment was valued at USD 3,307.7 million in 2013 with the largest revenue share in the overall NDDS in cancer therapy market. Over the past two decades, many nanoparticles such as Doxil (doxorubicin), Megace ES (megestrol acetate), Abraxane (paclitaxel), Myocet (doxorubicin), DepoCyt (liposomal cytarabine), and DaunoXome (daunorubicin citrate) have been approved as drug delivery systems for cancer therapy. NDDS in Cancer Therapy Market, by Technology Embolization Particles Current Technologies - Drug Eluting Beads - Others (PVA particles, microspheres, gelatin-based) Emerging Technologies - Selective Internal Radiation Therapy (SIRT) - TheraSphere - SIR-Spheres - Holmium-based Microspheres Liquid Embolics - Onyx (LES and HD-500) - TRUFILL nBCA LES Nanoparticles Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Embolization Particles Market Revenue, by Type Chapter 5 Global Liquid Embolics Market Revenue, by Brand Chapter 6 Global Nanoparticles Market Revenue Chapter 7 Global NDDS in Cancer Therapy Market, by Geography Chapter 8 Recommendations Companies Mentioned - Advanced Medical Isotope Corporation - BTG plc - Bind Therapeutics - Boston Scientific Corporation - CeloNova BioSciences - Cook Medical - Cospheric LLC - Covidien - Eckert & Ziegler BEBIG - EmboMedics - Terumo Medical Corporation. - Kobo Products - Merit Medical Systems - Mo-Sci Corporation - Nanobiotix - Polysciences - Sirtex Medical For more information visit http://www.researchandmarkets.com/research/ws..._in_cancer
BSX: 17.85 (-0.06), MMSI: 20.64 (-0.10)
SIR-Spheres® y-90 Resin Microspheres Recommended in New European Society of Medical Oncology (ESMO) Clinical Guidelines for Treating Metastatic Colorectal Cancer (mCRC)
CNW Group - Mon Sep 29, 8:13AM CDT
Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolisation, specifically with Yttrium-90 resin microspheres, as a clinically proven technology to "prolong time to liver tumour progression" in mCRC patients who have failed to respond to available chemotherapy options.
Sirtex Medical Inc. Expands Business into Brazil, Experiences Record Growth
Business Wire - Mon Sep 08, 9:00AM CDT
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, liver cancer therapies, announced today the expansion of its business in Latin America. Sirtex's SIR-Spheres(R) microspheres are now available to treat inoperable liver tumors in Brazil. The first SIR-Spheres microspheres treatments took place the first week of September at Hospital Sirio-Libanes in Sao Paulo. Sirtex received product approval from the Agencia Nacional de Vigilancia Sanitaria (ANVISA) for SIR-Spheres microspheres early in 2014.
Sirtex Medical Inc. Announces 33 Percent Dose Sales Growth of SIR-Spheres(R) microspheres in Fourth Quarter
Business Wire - Mon Jul 07, 9:00AM CDT
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced dose sales of SIR-Spheres(R) microspheres grew 33 percent on a unit basis in the Americas region for the quarter ending June 30, 2014, compared to the previous corresponding period.
Brachytherapy Global Strategic Business Report 2014: Competition Heats Up in the Brachytherapy Market
M2 - Thu Jun 12, 5:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zllh3/brachytherapy) has announced the addition of the "Brachytherapy - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Brachytherapy in US$ Thousands. The report provides separate comprehensive analytics for the US, Canada, Japan Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 36 companies including many key and niche players such as: - Best Medical International - Best Vascular - Boston Scientific - COOK Medical - C. R. Bard - Eckert & Ziegler Strahlen & Medizintechnik - Gammex - Nucletron - Oncura - Sirtex Medical - Theragenics - Varian Medical Systems - Xoft Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW - Brachytherapy - A Prelude - The US Leads the Brachytherapy Devices Market Developing Regions to Spearhead Growth - Brachytherapy Provides More Hope for Cancer Patients Compared to EBRT - Comparison of Brachytherapy Over EBRT in Prostate Cancer Treatment - Growing Cancer Cases in Developing Countries Bodes Well for the Brachytherapy Market - Recent Technological Advancements Show Promising Future for the Brachytherapy Market 2. MAJOR MARKET DRIVERS, TRENDS & ISSUES 3. RESEARCH & STUDY FINDINGS 4. PROSTATE CANCER A MAJOR BRACHYTHERAPY INDICATION 5. OTHER MAJOR BRACHYTHERAPY INDICATIONS 6. PRODUCT OVERVIEW 7. BRACHYTHERAPY EQUIPMENT 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET IV. COMPETITIVE LANDSCAPE For more information visit http://www.researchandmarkets.com/research/7z...chytherapy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
BSX: 17.85 (-0.06), VAR: 87.25 (-0.34)
How To Profit From Australia's Healthiest Biotechs: Wilson HTM's Shane Storey
Life Sciences Report - Seeking Alpha - Thu Apr 16, 2:14PM CDT
Australia will always be known as a trove of natural resources, but its most precious treasure is the abundance of entrepreneurs who are all too happy to develop the country's intellectual assets. Shane Storey, head of research at Australia-based...
PHG: 28.33 (+0.40), RMD: 56.20 (-0.26)
Sirtex: Update On Study Results
Russell Muldoon - Seeking Alpha - Mon Mar 23, 6:15AM CDT
(Editor's Note: Investors should be mindful of the risks of transacting is securities with limited liquidity, such as SXMDF. Sirtex's listing in Australia, SRX.AX, offers stronger liquidity.) SIRFLOX Trial Results Despite our understanding of the...
Sirtex Slips On Its Beads After Trial Miss
EP Vantage - Seeking Alpha - Tue Mar 17, 3:07PM CDT
In its announcement today Sirtex Medical ( OTCPK:SXMDF ) said it was pleased to report the preliminary results of its phase III Sirflox study, but frankly that seems unlikely. The trial failed, and Sirtex's dreams of having a first-line therapy for...
Sirtex Medical: Strong Demand And New Market Potential
Russell Muldoon - Seeking Alpha - Fri Mar 13, 7:19AM CDT
(Editor's Note: Investors should be mindful of the risks of transacting is securities with limited liquidity, such as SXMDF. Sirtex's listing in Australia, SRX.AX, offers stronger liquidity.) Sirtex Medical Limited is an Australian-based medical...
Onxeo: An Upcoming Mid-Sized Pharma With Ambitions
Logribel Biostocks - at Seeking Alpha - Thu Mar 12, 1:58PM CDT
MACK: 12.66 (+0.34), RNN: 0.71 (+0.01), PTBI: 7.98 (-0.36), DARA: 0.68 (-0.06), BIND: 6.24 (unch)
Sirtex Medical Inc. Half-Year Dose Sales Surge 28 Percent in Advance of SIRFLOX Primary Endpoint Announcement
Business Wire - Wed Feb 18, 8:13AM CST
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), has announced that dose sales of SIR-Spheres(R) Y-90 resin microspheres in the Americas region grew more than 28 percent for the first half of the company's fiscal year compared to the same period last year, with 3,390 doses supplied for the period July through December 2014. The gross sales in the region equate to $54.3M in the first half of the current fiscal year compared to $39.8M from the prior year, a 36.7% increase. Globally the company announced sales of 4,950 doses, an increase of 26.3% over the previous corresponding six-month period.
FOXFIRE and FOXFIRE Global Studies Complete Patient Enrolment
CNW Group - Thu Jan 29, 10:22AM CST
Combined data from more than 1,000 patients being collected to assess overall survival (OS) benefit of adding first-line SIR-Spheres® Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer (mCRC)
Novel Drug Delivery System (NDDS) in Cancer Therapy Market - Global Industry Analysis to 2020 for the $15 Billion Market
M2 - Wed Nov 12, 3:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/ws3rns/ndds_in_cancer) has announced the addition of the "NDDS in Cancer Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global market for NDDS in cancer therapy was valued at USD 3,655.3 million in 2013 and is expected to reach USD 15,984.2 million in 2020, growing at a CAGR of 23.7% during the forecast period from 2014 to 2020 The world is witnessing a continuous rise in the incidence of various types of cancer. Clinical benefits of embolic agents and nanoparticles over other therapy and drug delivery systems; technological advances leading to the development of new and innovative therapy; and expanding therapeutic indications of existing NDDS are some of the major factors expected to drive growth of the global NDDS in cancer therapy market during the forecast period from 2014 to 2020. On the other hand, factors such as high treatment cost associated with NDDS, strict regulatory pathways and cost associated with new product development may restrict market growth to some extent. One of the major opportunities in this market is nano-enabled drug delivery systems as this segment has been anticipated to grow at the highest CAGR of 24.7% during the forecast period. Embolization particles, liquid embolics and nanoparticles as drug delivery systems altogether comprise the global market for NDDS in cancer therapy. PVA particles, microspheres, drug eluting beads (DEB) and selective internal radiation therapy (SIRT) are the major products under the embolization particles market segment, while Onyx LES and TRUFILL nBCA LES are the two major liquid embolic system brands. The liquid embolics market segment is expected to grow at a CAGR of 4.9% during the forecast period from 2014 to 2020. Nanoparticles in novel drug delivery systems have emerged as a promising technology to treat patients suffering from various types of cancer. The market for nanoparticles segment was valued at USD 3,307.7 million in 2013 with the largest revenue share in the overall NDDS in cancer therapy market. Over the past two decades, many nanoparticles such as Doxil (doxorubicin), Megace ES (megestrol acetate), Abraxane (paclitaxel), Myocet (doxorubicin), DepoCyt (liposomal cytarabine), and DaunoXome (daunorubicin citrate) have been approved as drug delivery systems for cancer therapy. NDDS in Cancer Therapy Market, by Technology Embolization Particles Current Technologies - Drug Eluting Beads - Others (PVA particles, microspheres, gelatin-based) Emerging Technologies - Selective Internal Radiation Therapy (SIRT) - TheraSphere - SIR-Spheres - Holmium-based Microspheres Liquid Embolics - Onyx (LES and HD-500) - TRUFILL nBCA LES Nanoparticles Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Embolization Particles Market Revenue, by Type Chapter 5 Global Liquid Embolics Market Revenue, by Brand Chapter 6 Global Nanoparticles Market Revenue Chapter 7 Global NDDS in Cancer Therapy Market, by Geography Chapter 8 Recommendations Companies Mentioned - Advanced Medical Isotope Corporation - BTG plc - Bind Therapeutics - Boston Scientific Corporation - CeloNova BioSciences - Cook Medical - Cospheric LLC - Covidien - Eckert & Ziegler BEBIG - EmboMedics - Terumo Medical Corporation. - Kobo Products - Merit Medical Systems - Mo-Sci Corporation - Nanobiotix - Polysciences - Sirtex Medical For more information visit http://www.researchandmarkets.com/research/ws..._in_cancer
BSX: 17.85 (-0.06), MMSI: 20.64 (-0.10)
SIR-Spheres® y-90 Resin Microspheres Recommended in New European Society of Medical Oncology (ESMO) Clinical Guidelines for Treating Metastatic Colorectal Cancer (mCRC)
CNW Group - Mon Sep 29, 8:13AM CDT
Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolisation, specifically with Yttrium-90 resin microspheres, as a clinically proven technology to "prolong time to liver tumour progression" in mCRC patients who have failed to respond to available chemotherapy options.
Sirtex Medical Inc. Expands Business into Brazil, Experiences Record Growth
Business Wire - Mon Sep 08, 9:00AM CDT
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, liver cancer therapies, announced today the expansion of its business in Latin America. Sirtex's SIR-Spheres(R) microspheres are now available to treat inoperable liver tumors in Brazil. The first SIR-Spheres microspheres treatments took place the first week of September at Hospital Sirio-Libanes in Sao Paulo. Sirtex received product approval from the Agencia Nacional de Vigilancia Sanitaria (ANVISA) for SIR-Spheres microspheres early in 2014.
Sirtex Medical Inc. Announces 33 Percent Dose Sales Growth of SIR-Spheres(R) microspheres in Fourth Quarter
Business Wire - Mon Jul 07, 9:00AM CDT
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced dose sales of SIR-Spheres(R) microspheres grew 33 percent on a unit basis in the Americas region for the quarter ending June 30, 2014, compared to the previous corresponding period.
Brachytherapy Global Strategic Business Report 2014: Competition Heats Up in the Brachytherapy Market
M2 - Thu Jun 12, 5:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zllh3/brachytherapy) has announced the addition of the "Brachytherapy - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Brachytherapy in US$ Thousands. The report provides separate comprehensive analytics for the US, Canada, Japan Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 36 companies including many key and niche players such as: - Best Medical International - Best Vascular - Boston Scientific - COOK Medical - C. R. Bard - Eckert & Ziegler Strahlen & Medizintechnik - Gammex - Nucletron - Oncura - Sirtex Medical - Theragenics - Varian Medical Systems - Xoft Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW - Brachytherapy - A Prelude - The US Leads the Brachytherapy Devices Market Developing Regions to Spearhead Growth - Brachytherapy Provides More Hope for Cancer Patients Compared to EBRT - Comparison of Brachytherapy Over EBRT in Prostate Cancer Treatment - Growing Cancer Cases in Developing Countries Bodes Well for the Brachytherapy Market - Recent Technological Advancements Show Promising Future for the Brachytherapy Market 2. MAJOR MARKET DRIVERS, TRENDS & ISSUES 3. RESEARCH & STUDY FINDINGS 4. PROSTATE CANCER A MAJOR BRACHYTHERAPY INDICATION 5. OTHER MAJOR BRACHYTHERAPY INDICATIONS 6. PRODUCT OVERVIEW 7. BRACHYTHERAPY EQUIPMENT 8. RECENT INDUSTRY ACTIVITY 9. FOCUS ON SELECT PLAYERS 10. GLOBAL MARKET PERSPECTIVE III. MARKET IV. COMPETITIVE LANDSCAPE For more information visit http://www.researchandmarkets.com/research/7z...chytherapy About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
BSX: 17.85 (-0.06), VAR: 87.25 (-0.34)
